Opus Genetics (IRD) Projected to Post Earnings on Thursday

Opus Genetics (NASDAQ:IRD) is anticipated to release its earnings data on Thursday, March 6th. Analysts expect Opus Genetics to post earnings of ($0.02) per share and revenue of $11.10 million for the quarter.

Opus Genetics Price Performance

NASDAQ:IRD opened at $1.00 on Wednesday. The firm has a market cap of $31.57 million, a P/E ratio of -0.92 and a beta of 0.16. The firm’s 50 day moving average price is $1.16. Opus Genetics has a fifty-two week low of $0.81 and a fifty-two week high of $1.56.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Opus Genetics in a research report on Wednesday, February 19th.

Insider Buying and Selling at Opus Genetics

In other Opus Genetics news, CEO George Magrath purchased 100,000 shares of the business’s stock in a transaction on Thursday, December 26th. The shares were purchased at an average cost of $0.98 per share, for a total transaction of $98,000.00. Following the acquisition, the chief executive officer now owns 599,150 shares of the company’s stock, valued at approximately $587,167. This represents a 20.03 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.60% of the company’s stock.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.